5,163 Shares in Bio-Rad Laboratories, Inc. (NYSE:BIO) Purchased by Jump Financial LLC

Jump Financial LLC acquired a new stake in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) in the fourth quarter, according to its most recent disclosure with the SEC. The firm acquired 5,163 shares of the medical research company's stock, valued at approximately $1,667,000.

A number of other institutional investors have also added to or reduced their stakes in BIO. Gladius Capital Management LP increased its stake in Bio-Rad Laboratories by 65.8% in the 4th quarter. Gladius Capital Management LP now owns 121 shares of the medical research company's stock worth $39,000 after acquiring an additional 48 shares during the last quarter. Principal Securities Inc. purchased a new position in shares of Bio-Rad Laboratories in the fourth quarter valued at $41,000. GAMMA Investing LLC bought a new stake in Bio-Rad Laboratories in the fourth quarter worth $42,000. ING Groep NV purchased a new stake in Bio-Rad Laboratories during the third quarter valued at $44,000. Finally, Bfsg LLC bought a new position in Bio-Rad Laboratories during the fourth quarter valued at $77,000. 65.24% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other Bio-Rad Laboratories news, EVP Michael Crowley sold 3,000 shares of the company's stock in a transaction dated Tuesday, February 27th. The shares were sold at an average price of $336.00, for a total value of $1,008,000.00. Following the transaction, the executive vice president now directly owns 6,942 shares in the company, valued at approximately $2,332,512. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 17.50% of the company's stock.

Analyst Ratings Changes

A number of analysts have recently weighed in on BIO shares. UBS Group reduced their target price on shares of Bio-Rad Laboratories from $420.00 to $385.00 and set a "buy" rating on the stock in a report on Wednesday, May 8th. Royal Bank of Canada lowered their price objective on Bio-Rad Laboratories from $484.00 to $480.00 and set an "outperform" rating for the company in a research note on Friday, February 16th. StockNews.com cut Bio-Rad Laboratories from a "buy" rating to a "hold" rating in a report on Monday. Finally, Citigroup lowered Bio-Rad Laboratories from a "buy" rating to a "neutral" rating and decreased their price target for the company from $400.00 to $365.00 in a report on Wednesday, April 3rd. Two equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company's stock. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and an average target price of $461.00.

Bio-Rad Laboratories Trading Up 2.4 %

Shares of NYSE:BIO traded up $6.96 during trading hours on Wednesday, hitting $300.97. 234,828 shares of the company's stock traded hands, compared to its average volume of 206,969. The firm has a market capitalization of $8.58 billion, a P/E ratio of -29.05 and a beta of 0.94. The business has a fifty day moving average price of $310.81 and a 200-day moving average price of $313.81. Bio-Rad Laboratories, Inc. has a 1 year low of $261.59 and a 1 year high of $431.79. The company has a debt-to-equity ratio of 0.13, a current ratio of 6.57 and a quick ratio of 4.89.

Bio-Rad Laboratories (NYSE:BIO - Get Free Report) last posted its quarterly earnings data on Tuesday, May 7th. The medical research company reported $2.29 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.04 by $0.25. Bio-Rad Laboratories had a positive return on equity of 3.59% and a negative net margin of 12.37%. The company had revenue of $610.82 million during the quarter, compared to analysts' expectations of $619.09 million. During the same quarter in the previous year, the business earned $3.34 EPS. Bio-Rad Laboratories's revenue was down 9.8% compared to the same quarter last year. Equities analysts expect that Bio-Rad Laboratories, Inc. will post 10.41 earnings per share for the current year.

Bio-Rad Laboratories Profile

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.